Number of participants with any serious adverse events · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of adverse events requiring discontinuation of treatment ‐ not reported · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants experiencing treatment discontinuation caused… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing disability progression · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with any adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants with gadolinium‐enhancing T1 lesions on MRI compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants with new or enlarging T2‐hyperintense lesions… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants experiencing disability progression · primary progressive multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with placebo (low certainty).
1 finding from 1 review
Number of participants with any adverse events · primary progressive multiple sclerosis
Ocrelizumab probably leads to higher number of participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Pain at 12 months or more (long-term postobturation pain) · People aged 10 years or above requiring root canal treatment; permanent teeth with completely formed apex and without internal resorption
1 finding from 1 review
Sinus or fistula formation at last · People aged 10 years or above requiring root canal treatment; permanent teeth with completely formed apex and without internal resorption
It is very uncertain whether single-visit root canal treatment changes sinus tract or fistula formation compared with multiple-visit root canal treatment (two or more visits) (very low certainty).
1 finding from 1 review
Postoperative pain intensity in the immediate postobturation period (up to 72 hours), continuous (VAS) · People aged 10 years or above requiring root canal treatment; permanent teeth with completely formed apex and without internal resorption
Single-visit root canal treatment showed no clear difference in postoperative pain intensity in the immediate postobturation period… compared with multiple-visit root canal treatment (two or more visits) (low certainty).
1 finding from 1 review
Pain at 1 month · People aged 10 years or above requiring root canal treatment; permanent teeth with completely formed apex and without internal resorption
1 finding from 1 review
One study (Dhyani 2022) reported pain at 1 month: 60 teeth (all vital at enrolment, mechanical NiTi), 0 events (no participant reported pain at 1 month); no meta-analysis
1 study · 60 participants
GRADE not reported
Postobturation pain at 1 week · People aged 10 years or above requiring root canal treatment; permanent teeth with completely formed apex and without internal resorption
It is very uncertain whether single-visit root canal treatment changes postobturation pain at 1 week compared with multiple-visit root canal treatment (two or more visits) (very low certainty).
1 finding from 1 review
Radiological failure (periapical radiolucency) after at least 1 year · People aged 10 years or above requiring root canal treatment; permanent teeth with completely formed apex and without internal resorption
Single-visit root canal treatment showed no clear difference in radiological failure (periapical radiolucency) after at least 1 year compared with multiple-visit root canal treatment (two or more visits) (moderate certainty).
1 finding from 1 review
Intervention not reported
Subjective memory measures ‐ intermediate EMQ, MSNQ, CFQ, MFQa · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Objective verbal memory measures ‐ intermediate CVLT, AVLT, HVLT, VLT, SRT, MUSICa · people with multiple sclerosis
1 finding from 1 review